- Report
- February 2025
- 200 Pages
Global
From €4029EUR$4,490USD£3,467GBP
- Report
- May 2024
- 130 Pages
Global
From €5831EUR$6,499USD£5,019GBP
- Report
- May 2024
- 128 Pages
Global
From €5831EUR$6,499USD£5,019GBP
- Report
- October 2024
- 331 Pages
Global
From €7133EUR$7,950USD£6,140GBP
- Report
- February 2022
- 220 Pages
Global
From €8524EUR$9,500USD£7,337GBP
- Drug Pipelines
- April 2024
- 50 Pages
Global
From €1346EUR$1,500USD£1,158GBP
- Report
- March 2024
- 159 Pages
Global
From €7133EUR$7,950USD£6,140GBP
- Report
- July 2022
- 63 Pages
Global
From €1795EUR$2,000USD£1,545GBP
- Report
- April 2025
- 50 Pages
Global
From €2378EUR$2,650USD£2,047GBP
- Book
- January 2010
- 616 Pages
Ivabradine is a drug used to treat cardiovascular diseases, such as chronic heart failure and stable angina. It works by reducing the heart rate, which helps to reduce the workload on the heart and improve its efficiency. It is usually prescribed in combination with other drugs, such as beta-blockers and ACE inhibitors. Ivabradine is available in both oral and intravenous forms.
Ivabradine is a relatively new drug, having been approved by the US Food and Drug Administration in 2015. It has been shown to be effective in reducing the risk of hospitalization due to heart failure and improving quality of life in patients with chronic heart failure.
The market for Ivabradine is growing, as more and more patients are being prescribed the drug. It is becoming increasingly popular as a treatment for cardiovascular diseases, due to its effectiveness and safety profile.
Some of the companies in the Ivabradine market include Sanofi, Novartis, and AstraZeneca. Show Less Read more
